European Biotech Acquisition Corp.

European Biotech Acquisition Corp. (Nasdaq: EBAC) is a blank-check company formed to pursue a merger, capital stock exchange, asset acquisition, or similar business combination with one or more businesses in the European life sciences and biotechnology sector. The company completed its initial public offering in 2021 and filed this Form 10-Q with the SEC on May 16, 2022, covering quarterly operating activity during its search period. As of the filing date, EBAC remained in the target-identification phase, with its sponsor focused on opportunities across the European biopharma and healthcare landscape. Investors and analysts tracking SPAC activity in the life sciences space can access EBAC's full filing history, timeline data, and comparable deal metrics by signing up for SpacDesk.